Clinical Trial

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young female populations aged 9-17 years.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-29; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-07-28
Trial Details
NCT Number NCT06243666
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China
Conditions Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection
Enrollment 2,188 participants
Start Date 2024-02-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-31